| EDITORIALS |
| 348 | Women in medicine: The Henry Higgins problem
|
| 350 | How do we improve health care? The example of missed opportunities to address chronic wet cough in children in remote Australia
|
| 352 | One bronchodilator or two? Translating clinical trials into clinical practice
|
| 354 | Postural changes from ventilatory gas exchange in pulmonary hypertension: Is it a practical solution to a complex question?
Belinda N Rivera-Lebron MD, MS; Karla J Cruz Morel MD; Michael G Risbano MD, MA
10.1111/resp.13691 |
| 356 | Obesity hypoventilation syndrome: Stretching the health dollar
|
| 358 | BPAP for CPAP failures: For the many or the few
|
| COMMENTARY |
| 360 | Equality for women in respiratory and sleep medicine in the Asia-Pacific region: Opportunities for change
Natasha Smallwood BMedSci, MBBS, SpecCertPallCare, MSc (Epid), MRCP, FRACP, PhD; Megan Rees MBBS, DTMH, MRCP, FRACP, PhD
10.1111/resp.13773 |
| INVITED REVIEW SERIES |
| New frontiers in sleep-disordered breathing |
| 363 | Strategies to augment adherence in the management of sleep-disordered breathing
|
| 372 | Advances in non-invasive positive airway pressure technology
|
| ORIGINAL ARTICLES |
| Bronchiectasis |
| 383 |
We won't find what we don't look for: Identifying barriers and enablers of chronic wet cough in Aboriginal children
Pamela Laird, Roz Walker, Mary Lane, Anne B Chang, André Schultz
10.1111/resp.13642
Chronic wet cough and its relationship with the development of chronic suppurative lung disease in Aboriginal children is not widely appreciated by health practitioners. There is a need for health practitioners to receive training in culturally informed management of chronic wet cough and healthcare systems to facilitate chronic disease management. |
| COPD |
| 393 | Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long-acting bronchodilator-naïve COPD patients: A pooled analysis
Shigeo Muro, Hajime Yoshisue, Konstantinos Kostikas, Petter Olsson, Pritam Gupta, Jadwiga A Wedzicha
10.1111/resp.13651
Data are limited on initial treatment with indacaterol/glycopyrronium (IND/GLY) versus mono long-acting muscarinic antagonist (LAMA) in long-acting bronchodilator (LABD)-naïve chronic obstructive pulmonary disease (COPD) patients. This pooled analysis of ARISE, SHINE and SPARK trials demonstrated improvements with IND/GLY in lung function, daily symptoms, dyspnoea, health-related quality of life and rescue medication use versus tiotropium or GLY in LABD-naïve COPD patients. |
| 401 | Comparison of pre- and post-bronchodilator lung function as predictors of mortality: The HUNT Study
Laxmi Bhatta, Linda Leivseth, David Carslake, Arnulf Langhammer, Xiao-Mei Mai, Yue Chen, Anne H Henriksen, Ben M Brumpton
10.1111/resp.13648
Few previous studies have compared the discrimination ability of pre-BD and post-BD lung function in predicting mortality. We found post-BD is slightly better than pre-BD to predict mortality using percent-predicted forced expiratory volume in the first second (FEV1), FEV1 z-score, FEV1 quotient (FEV1Q) or modified Global Initiative for Chronic Obstructive Lung Disease (GOLD) categories. However, among people with chronic obstructive pulmonary disease (COPD), mortality was similarly predicted using GOLD grades. |
| Interstitial Lung Disease |
| 410 | Long-term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: Results from INPULSIS®-ON
Jin Woo Song, Takashi Ogura, Yoshikazu Inoue, Zuojun Xu, Manuel Quaresma, Susanne Stowasser, Wibke Stansen, Bruno Crestani
10.1111/resp.13647
In a subgroup analysis of data from the open-label extension of the INPULSIS® trials, INPULSIS®-ON, the effect of nintedanib on slowing disease progression in Asian patients with idiopathic pulmonary fibrosis was sustained over the long term. Long-term treatment with nintedanib had an acceptable safety and tolerability profile. |
| 417 | Mesenchymal stem cells reduce ER stress via PERK-Nrf2 pathway in an aged mouse model
Eun Joo Lee, Nayra Cárdenes, Diana Álvarez, Jacobo Sellarés, John Sembrat, Paola Aranda, Yating Peng, Jordan Bullock, Seyed M Nouraie, Ana L Mora, Mauricio Rojas
10.1111/resp.13646
We investigated the mechanisms by which mesenchymal stem cells (MSC) protect aged mice after bleomycin-induced lung injury. Increased endoplasmic reticulum (ER) stress happens in the lungs of idiopathic pulmonary fibrosis (IPF) patients and in bleomycin-induced lung fibrosis in mice, in which we identified a main pathway by which MSC reduce ER stress. |
| Pulmonary Vascular Disease |
| 427 | Non-invasive screening using ventilatory gas analysis to distinguish between chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension
Mina Akizuki, Koichiro Sugimura, Tatsuo Aoki, Takaaki Kakihana, Shunsuke Tatebe, Saori Yamamoto, Haruka Sato, Kimio Satoh, Hiroaki Shimokawa, Masahiro Kohzuki
10.1111/resp.13618
Differentiating between chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) using non-invasive techniques remains challenging. Ventilatory gas analysis in different postures is a useful, non-invasive bedside method to screen for the presence of pulmonary hypertension (PH) and distinguish between CTEPH and PAH. |
| Sleep and Ventilation |
| 435 |
Obesity hypoventilation syndrome treated with non-invasive ventilation: Is a switch to CPAP therapy feasible?
Maria P Arellano-Maric, Christine Hamm, Marieke L Duiverman, Sarah Schwarz, Jens Callegari, Jan H Storre, Claudia Schmoor, Marc Spielmanns, Wolfgang Galetke, Wolfram Windisch
10.1111/resp.13704
A total of 42 obesity hypoventilation syndrome (OHS) patients undergoing home non-invasive ventilation (NIV) therapy were switched to a 4−6-week period of continuous positive airway pressure (CPAP) therapy. This protocol proved to be safe and well-tolerated by patients. There was no impairment in quality of life, sleep parameters or lung function. These data could significantly reduce costs for the health system. |
| 443 | BPAP is an effective second-line therapy for obese patients with OSA failing regular CPAP: A prospective observational cohort study
Athanasius Ishak, Michelle Ramsay, Nicholas Hart, Joerg Steier
10.1111/resp.13674
There is a lack of effective alternative treatments for patients with obstructive sleep apnoea (OSA) who do not tolerate continuous positive airway pressure (CPAP) therapy. We investigated whether bilevel positive airway pressure (BPAP) could be an effective second-line therapy in this cohort of patients and found that BPAP significantly improved adherence and symptom control when compared to CPAP. |
| CONTEMPORARY CONCISE REVIEW |
| 449 | Contemporary Concise Review 2019: Chronic obstructive pulmonary disease
|
| LETTER FROM ASIA-PACIFIC AND BEYOND |
| 455 | Letter from Jordan
|
| FORUM AND DEBATE |
| Correspondence |
| 456 | Step-down from non-invasive ventilation to continuous positive airway pressure: A better phenotyping is required
Maxime Patout MD; Edouard Dantoing MD; Marielle De Marchi MD; Nicholas Hart MD, PhD; Patrick B Murphy MD, PhD; Antoine Cuvelier MD, PhD
10.1111/resp.13746 |
| 457 | Step-down from non-invasive ventilation to continuous positive airway pressure: A better phenotyping is required – Reply
|
